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Zika virus (ZIKV) has two lineages: African and Asian. Mosquito-borne ﬂaviviruses are
thought to replicate initially in dendritic cells and then spread to lymph nodes and the
blood stream. Risk for infection through blood transfusion, sexual practices and perinatal
transmission exists. The possible routes of perinatal transmission are during delivery,
breastfeeding and by close contact between the mother and her newborn. Also, muco-
cutaneous exposures to the virus by infected blood or monkey bite, organ transplantation
or hemodialysis are the other routes of ZIKV transmission. There are two types of ZIKV
infection; Zika fever and congenital infection. Clinical presentation of Zika fever varies
from asymptomatic infections to a self-limiting febrile disease with low grade fever,
conjunctivitis, maculopapular rash, headache, retro-orbital pain and arthritis/arthralgia
with periarticular edema, myalgia, vertigo, vomiting and asthenia. This clinical feature
could be mistaken for dengue or chikungunya fevers. Microcephaly is the most important
and frequently reported clinical picture of suspected congenital Zika syndrome. Labo-
ratory tests are needed for diagnosis of ZIKV infection, because there is no known
pathognomonic clinical, biochemical or radiological features. RT-PCR is the most well-
liked assay. Serum samples are tested by immunoglobulin G ELISA with ZIKV antigen.
Samples are also tested by immunoglobulin M ELISA. There is no certiﬁed vaccine or
therapeutic medication. In asymptomatic or uncomplicated patients, treatment is not
necessary.1. Introduction
Zika virus (ZIKV) is an arbovirus of the family Flaviviridae
[1,2]. There are some other mosquito-borne ﬂaviviruses which
are important as public health issues including yellow fever,
dengue, St. Louis encephalitis, West Nile and Japanese
encephalitis viruses [3,4].
ZIKV has two families: African and Asian. In 2007, an
epidemic was generated by the Asian family of ZIKV on Yap
Island, Micronesia; it then broaden to French Polynesia and
other regions of the South Paciﬁc and led to extensive epidemicsin 2013 and 2014; following this ZIKV came in the Americas in
2015, causing an estimated 1.5 million cases in Brazil in 2015
[5]. A new report of an association between ZIKV infection and
an epidemic of microcephaly among Brazilian neonates attracted
universal attention. ZIKV spreads fast from Africa and Asia to
the Americas and Europe and the “congenital Zika syndrome”
incidence has caused the World Health Organization (WHO)
to notify the ZIKV epidemic as a public health crisis of the
world at the beginning of February 2016 [6].
At ﬁrst ZIKV infection was reported in Uganda in 1947 and
sporadic cases were reported from 1960s in Asia and Africa [1,7–
9]. After 2 years, several ZIKV isolates were obtained from
Aedes spp. in Africa (Aedes africanus) and Malaysia [Aedes
aegypti (Ae. aegypti)], involving these species as likely
epidemic or enzootic vectors. Several ZIKV human isolates
were also obtained in the 1960s and 1970s from East and
West Africa. Additional serologic studies in the 1950s and
1960s detected ZIKV infections among humans in Egypt,
Nigeria, Uganda, India, Malaysia, Indonesia, Pakistan,
Thailand, North Vietnam and Philippines. Such data proposes article under the CC BY-NC-ND license (http://
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and north of the Wallace Line [10,11].
In May 2015, ﬁrst patients with ZIKV infection were re-
ported in Brazil and afterward in Colombia. Co-infection with
dengue (DENV), chikungunya and ZIKV was reported in the
same patients [12].
However, the clinical picture of ZIKV infection has been
poorly described to date, since it causes a benign, self-limiting
illness in most people; therefore, ZIKV infection has possibly
been underreported in the endemic places [13–15].
In this article, we review the available literatures that may
beneﬁt clinicians to obtain necessary information regarding
ZIKV infection.
2. Epidemiology
At the earliest during a study on yellow fever virus, ZIKV
was isolated from the blood of a febrile sentinel Rhesus monkey
in Zika jungle of Uganda in 1947. In 1948, ZIKV was isolated
from Aedes africanus mosquitoes indicating that the virus might
be mosquito-borne [4].
Zika virus has been quickly emerging in the western hemi-
sphere over the past few months. It was ﬁrst detected in Brazil, in
the northeast and was subsequently recognized in other states and
several South American countries including Colombia, Ecuador,
Suriname, Venezuela, French Guyana and Paraguay. Trans-
mission has been known in Central America (Panama, El Salva-
dor, Honduras andGuatemala), theCaribbean (Martinique, Puerto
Rico, Dominican Republic and Haiti) and Mexico. Transmission
also occurred in travelers returning from the infected regions to
non-endemic countries including United States, Canada, Japan
andWestern Europe. Since January 2016, a sum of 20 countries in
the Americas has reported ZIKV infections [16].
Several Aedes species have been reported to be probable
vectors of ZIKV including Aedes hensilli in Yap, Ae. aegypti
and Aedes polynesiensis in French Polynesia. Ae. aegypti and
Aedes albopictus are present in much of the Americas including
many parts of the Southeastern and South Central United States
as well as Hawaii [16].
In early 2015, an outbreak of ZIKV occurred in the state of
Rio Grande do Norte, Brazil. Results of analysis revealed a high
likeness of the sequences with Asian lineage. One theory
regarding the introduction of ZIKV in Brazil is the arrival of the
new emergent virus in 2014, during FIFA World Cup. In March
2015, another outbreak of ZIKV was occurred in the state of
Bahia. The results of investigation on this outbreak showed that
the obtained ZIKV sequences belonged to the Asian lineage with
99% identity with a sequence from a ZIKV isolate from French
Polynesia and extend to other Paciﬁc Islands. Since no endemic
ZIKV endangered any of the Paciﬁc countries during the FIFA
World Cup, it has been hypothesized that the virus invaded
Brazil through another occurrence that was held in Rio de
Janeiro in August 2014, the “Va'a World Sprint Championship
canoe race” where countries including French Polynesia, New
Caledonia, Cook Islands and Easter Islands attended [17,18].
3. Virology
ZIKV is an approximately 11 kb positive-sense RNA virus
that belongs to the genus Flavivirus in the family Flaviviridae
[4,16]. Virions of ZIKV are 40–60 nm in diameter, spherical in
shape and have a lipid envelope. The genome of ZIKA is asingle-stranded RNA which has 10794 nucleotides encoding
3 419 amino acids and contains two ﬂanking untranslated re-
gions (30 and 50 untranslated regions) and a single long open
reading frame encoding a polyprotein that is infolded in capsid,
precursor of membrane, envelope (E) and 7 non-structural (NS)
proteins (50-C-prM-ENS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-
30) [3,16,19]. The genomic RNA has a single long open reading
frame ﬂanked by 50- and 30-terminal non-coding regions that
shape speciﬁc secondary structures necessary for genome
replication and translation [16,19].
A key component on the surface of the virus is E protein that
plays a role in the receptor binding and membrane fusion. The
domain III of E protein includes a group of epitopes which are
targets in neutralizing antibodies, serological tests and vaccines.
Mosquito vectors adaptation and easy transmission of virus may
be related to loss of N154 glycosylation site in the E protein. In
addition, NS1 codon usage modiﬁcation to human housekeeping
genes that could make viral replication easier and increase viral
titers may be related to the new spread of the Asian lineage of
ZIKV to the Americas and Oceania [4].
4. Pathogenesis
Pathogenesis of ZIKV is almost unknown; however, it is
found that mosquito-borne ﬂaviviruses initially replicate in
dendritic cells close to the inoculation site and then spread to
lymph nodes and the blood. Although ﬂaviviral replication is
found to occur in cellular cytoplasm, studies suggest that ZIKV
antigens can be found in nucleus of the infected cells. Moreover,
infectious ZIKV has been detected in human blood before the
beginning of symptoms [14].
After the replication, ZIKV may distribute from the lym-
phatics and blood stream to infect other organs of the body such
as myocardium, central nervous system, skeletal muscles and to
the fetus. The virus replication in astroglial cells and neurons in
the brain of infected suckling mice result in neuronal degener-
ation, cellular inﬁltration and alleviation in the brain. Further-
more, the evidence of inﬂammation is found in myocardium and
skeletal muscles in the infected mice. The neurotropism and
tenacity of ZIKV may explain neurological complications such
as microcephaly in congenital ZIKV infection [4].
5. Transmission
Rhesus monkeys can be the source in natural habitats of
human infections through the bite of Ae. aegypti and Aedes
albopictus in infected monkeys and subsequent transmission to
vulnerable human hosts [20,21]. Aedes mosquitoes are found to be
the most substantial vectors for ZIKV transmission; however,
some Anopheles, Culex, Eretmapodites and Mansonia species
have also been suggested as vectors. They bite both in house
and in the open air and mostly during daytime [4,22]. It
appears that viremia can start up to 10 days before onset of
symptoms [23,24].
ZIKV is most likely maintained in a sylvatic cycle that in-
cludes non-human primates and mosquitoes with cyclic epizo-
otics among monkeys in Uganda. Another emerging facet of the
zoonosis has been the probable transmission through bites of
monkeys and other non-human primates. In the sylvatic trans-
mission cycle, humans possibly serve as incidental hosts; how-
ever, in areas without non-human primates, humans probably
serve as primary intensiﬁcation hosts [3,21].
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contact [17,26] and perinatal transmission [15] exists. The likely
routes of perinatal transmission are transplacental during
delivery, breastfeeding and by close contact between the
mother and her baby through saliva and other body ﬂuids
exchange [20,21,23,27,28]. Sexual transmission of ZIKV seems to
be highly probable, mainly in patients who have blood in
semen. The sexual transmission of ZIKV to the female partner
may infect the existing fetus. Other supposed routes of
transmission are mucocutaneous contact to the virus in
infected blood or via monkey bite, hemodialysis or
transplantation. ZIKV infections have been documented
through laboratory exposure. It is unidentiﬁed whether ZIKV
can be spread by respiratory droplets [4,21,29,30].
Occurrence in birds and possible transmission from avian
species to humans through insect intermediates has not been
studied [7,23], although antibodies have been detected in several
animal species [3].
6. Clinical presentations and differential diagnosis
Up to 80% of ZIKV infections may be asymptomatic. Pa-
tients with compromised immunity can be more vulnerable to
develop severe disease if infected with ZIKV [5]. Symptoms
expand after a bite by a Zika-infected mosquito with an incu-
bation period of 2–14 days. ZIKV infection has two types
including Zika fever and congenital infection [4].
Clinical presentations of Zika fever vary from asymptomatic
infections to a self-limiting febrile sickness, presenting as a
“dengue-like” syndrome with low fever, bilateral conjunctivitis,
maculopapular rash, headache, retro-orbital pain and arthritis/
arthralgia with edema of the tiny joints of hands and feet,
myalgia, vertigo and asthenia [1,4,10,17,30]. Occasionally, sore
throat, cough and loose bowels are reported [31]. Conjunctivitis
in Zika fever is non-purulent and bilateral and the rash is re-
ported to be erythematous and generalized that spreads from the
face to the both limbs. There are some important systemic
symptoms that are presented by high fever, chills, rigors, sore
throat, hypotension, cervical, submandibular, axillary and/or
inguinal lymphadenopathies. In addition, digestive symptoms
may also be present including nausea, vomiting, diarrhea, con-
stipation, abdominal pain and aphthous ulcers. Patients with
genitourinary symptoms including hematuria, dysuria, perineal
pain and hematospermia often have measurable virus particles in
urine and/or semen [4]. This clinical feature can be wrong for
dengue or chikungunya fevers [3]. Some presentations may
distinguish Zika fever from chikungunya and dengue fever
including more eminent edema of the extremities, less severe
headache and milder thrombocytopenia reported in the former.
Additionally despite dengue fever, hemorrhagic complications
are not reported in Zika fever. Moreover, arthralgia in Zika
fever is not as much as that of chikungunya fever [4,13,17].
These presentations are not pathognomonic and laboratory
tests are required to exclude other causes of febrile diseases.
As a matter of fact, Zika can be misdiagnosed during the
acute stage because of nonspeciﬁc signs and symptoms.
However, neurologic complications including Guillain-Barre´
syndrome (GBS) have been reported [4,13].
The rashes may be pruritic and usually resolves within the
ﬁrst week, but may remain for two weeks. It is important to
exclude other infections such as chikungunya, DENV, measles
virus, rubella virus, parvovirus B19, enterovirus, adenovirus andrickettsial infection. Duration of arthralgia is 3–5 days but, in
some patients, arthralgia may be persistent or recurrent for more
than 30 days after symptom initiation. Lymphadenopathies may
last for 14 days after symptom onset and other infectious dis-
eases including mononucleosis-like syndrome, toxoplasmosis
and Streptococcus pyogenes should be came in mind [4,32,33].
6.1. Congenital Zika syndrome
Microcephaly is the most common clinical presentation of
congenital Zika syndrome. Neonates and fetuses with suspected
ZIKV infection are also found to have some other malformations
including low birth weight, anasarca, unnecessary scalp skin,
polyhydramnios and arthrogryposis. Neurological complications
may also exist encompassing polymalformative syndromes, ce-
rebral lesions, brainstem dysfunction and absence of swallowing.
Ophthalmological deﬁciencies include cataract, intraocular cal-
ciﬁcations, asymmetrical eye sizes, optic nerve hypoplasia,
macular atrophy, iris coloboma and lens subluxation. Other fea-
tures such as hepatosplenomegaly, rash and chorioretinitis have
not been reported [4]. It is important to mention that there are no
large studies to present a causal relation between ZIKV in the
fetus and the congenital anomalies after exclusion of other
infections. Hence, exclusion of the “TORCH” (toxoplasmosis,
other infections, rubella, cytomegalovirus, herpes simplex
virus-2 or neonatal herpes simplex) infections is needed for the
diagnosis of congenital Zika syndrome. As a matter of fact, there
are numerous etiological agents related to microcephaly including
genetic disorders, drug intoxication of the pregnant woman (i.e.
use of alcohol, cocaine or antiepileptic drugs), maternal malnu-
trition and transplacental infections [4,23,34–38].
The risk of microcephaly in the neonates appears to be
mostly occurred in the ﬁrst trimester of pregnancy [23]. Heart and
muscle abnormalities should also be excluded. It is likely that
intrauterine ZIKV infections that happen at a later time of the
pregnancy may have different presentations, either with less
severe abnormalities such as deafness, eye lesions and mental
retardation [4].
6.2. Complications
Heart complications and immune thrombocytopenic purpura
have also been found in a few cases. In Eastern Nigeria, jaundice
was reported in patients with serological or virological evidence
of ZIKV infection that also had malaria, microﬁlaremia and
sickle cell anemia. Furthermore, the incidence rate of GBS cases
was 20-fold higher than expected at the epidemic time of ZIKV
[4,15,24,33].
Other abnormalities related to ZIKV infection include en-
cephalitis, meningoencephalitis, myelitis, paresthesia, vertigo,
facial paralysis, photophobia and hypertensive iridocyclitis and
auditory features [4]. The ﬁndings of a relation between ZIKV
infection and hydrops fetalis propose that the virus may make
damage to tissues in addition to the fetal central nervous
system. New studies found that histopathologic ﬁndings and
detection of ZIKV in newborns and fetuses with microcephaly
were restricted to the brain and placenta [39].
No death, hospitalization or hemorrhagic complication was
observed during the epidemic on Yap Island; however, in Brazil,
three deaths have been observed in relation with ZIKV. Newly
in Colombia, death of an adolescent with sickle cell anemia has
been reported [4,34].
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Laboratory approval is necessary for diagnosis of Zika
infection considering that there is no pathognomonic presenta-
tion that differentiates Zika fever from other infections as well as
congenital ZIKV infection from other etiologies of congenital
abnormalities [4].
There are two types of diagnosis for ZIKV. The ﬁrst type
includes the detection of the virus or viral particles. RT-PCR,
immunoassay and virus isolation have been invented to iden-
tify ZIKV RNA, viral proteins and live virus, respectively. RT-
PCR is the most well-liked assay because of its high sensitivity
and speciﬁcity, while virus isolation is the gold standard but
requires more laboratory facilities for cell culture. Most impor-
tantly, viral culture is not usually performed. The second type of
diagnosis is based on the detection of antibodies [5,30]. Serums
samples are examined by immunoglobulin G ELISA with
ZIKV antigen as well as the samples are tested by
immunoglobulin M (IgM) ELISA with the viral antigens of
Zika virus, DENV, yellow fever virus, Japanese encephalitis
virus and Murray Valley encephalitis virus [11]. Furthermore,
plaque reduction neutralization assay has improved speciﬁcity
more than immunoassays, but may still earn cross-reactive re-
sults in secondary ﬂavivirus infections [14]. Although serologic
testing can identify the virus, dengue may make false positive
results; therefore, positive results must be conﬁrmed by the
plaque reduction neutralization assay [13,16].
The cross-reactivity of antibodies between ﬂaviviruses con-
ﬁnes apply of serology [29]. Cross-reactivity is more often
renowned with dengue virus than with yellow fever, Japanese
encephalitis, Murray Valley encephalitis or West Nile viruses.
Cases with primary ZIKV infection and precedent DENV
infection are more likely to produce higher titer of IgM or
neutralizing antibodies in opposition to ZIKV than against
DENV. IgM may be identiﬁed on as early as day three of
symptom beginning and may continue for over two months. IgM
antibodies to dengue virus usually do not continue longer than
90 days. Neutralizing antibodies recognized by the plaque
reduction neutralization test have more speciﬁcity than IgM
detection by ELISA; however, the results may be indeterminate
in patients who have prior vaccination history in opposition to
other ﬂaviviruses [4,5,7,14].
Quick and precise diagnosis of ZIKV infection has been
earned by the application of RT-PCR via primers that target the
E or NS5 gene [4,7]. RT-PCR may let simultaneous detection of
more than ﬁfty different ﬂaviviruses. Urine and semen samples
may have higher viral loads than serum samples and may be
tirelessly positive for more than 30 and 62 days after symptom
onset, respectively. As dating of symptoms beginning is not easy
during Zika fever, using a mixture of samples including blood,
saliva, urine, semen and nasopharyngeal is recommended
[4,7,13,19,30].
Laboratory proﬁles are often normal. Although, some patients
may have some hematological changes including leukopenia,
neutropenia, lymphopenia, monocytosis, thrombocytopenia and
high serum levels of lactate dehydrogenase, aspartate amino-
transferase, ﬁbrinogen, g-glutamyl transferase, ferritin, C-reactive
protein and erythrocyte sedimentation rate [4].
Indications for testing during acute ZIKV disease should be
supposed in individuals who: (a) traveled to or resided in an
affected area within the past two weeks; (b) have 2 of the ad-
vents including fever, rash, conjunctivitis or arthralgia.For probable acute ZIKV disease: (a) if symptoms have been
in attendance for less than seven days, test serum and if obtained
for other reasons, cerebrospinal ﬂuid for ZIKV RNA by RT-
PCR; (b) if ZIKV RNA is not identiﬁed and symptoms have
been present for equal or more than four days, check serum for
ZIKV IgM and neutralizing antibodies and dengue virus IgM
and neutralizing antibodies.
Acute ZIKV disease should also be supposed in an infant
during the ﬁrst two weeks of living: (a) whose mother traveled to
or resided in an affected area within two weeks of delivery; (b)
who has equal or more than two of the advents including fever,
rash, conjunctivitis or arthralgia.
Indications for testing regarding congenital infection include:
(a) an infant with microcephaly or intracranial calciﬁcations born
to a woman who traveled to or resided in a place with ZIKV
transmission as she was pregnant or (b) an infant born to a
mother with a positive test for ZIKV infection.
For all infants with probable congenital ZIKV infection, do
the following: (a) physical examination including size of
occipito-frontal circumference, length, weight and evaluation of
gestational age; (b) assessment for neurologic abnormalities,
dysmorphic features, splenomegaly, hepatomegaly and rash or
other skin lesions; (c) cranial ultrasound; (d) assessment of
hearing by otoacoustic emissions or auditory brainstem response
testing, either before discharge from the hospital or within one
month after delivery; (e) examination of the retina, either before
discharge from the hospital or within one month after labor.
Other important evaluations for infants with microcephaly
include the following: (a) consultation with a pediatric neurol-
ogist to decide other evaluation including ultrasound, comput-
erized tomography scan, and magnetic resonance imaging; (b)
testing for other infections such as syphilis, toxoplasmosis,
rubella, cytomegalovirus, and herpes simplex virus infections.
For infants, RT-PCR assay should be conducted for ZIKV
RNA and ZIKV and dengue virus IgM and neutralizing antibodies
on serum composed from the umbilical cord or straight from infant
within two days of delivery, if probable. It should be incorporated
with histopathologic evaluation of the placenta and umbilical cord
with ZIKV immunohistochemical staining and RT-PCR.
For all infants with likely congenital ZIKV, the most
important recommended long-term follow-ups are: (a) con-
ducting hearing screen at six months of age; (b) evaluating
occipito-frontal circumference and developmental characteristics
during the ﬁrst year of living [34,36,37,40].
8. Treatment
There is no certiﬁed therapeutic or preventive medication
available for ZIKV. Treatment is often not required for patients
with asymptomatic or uncomplicated Zika fever [4,22,23].
Two strategies can be followed for ZIKV antiviral invention.
The ﬁrst is to re-target existing clinical medications which have
been previously developed for other disease indications for ZIKV
treatment. Some of the drugs did show antiviral activity in cell
culture. The second strategy is to build up inhibitors of ZIKV. The
experience gained from DENV drug invention can be applied to
ZIKV; however, concern should be considered when extrapo-
lating DENV antiviral experience to ZIKV, because the viruses
are genetically separate and the biology of the two viruses can be
very diverse. Therapeutic antibodies can also be applied for
treatment of ZIKV. One challenge for the development of ZIKV
antiviral is the high risk of adverse effects for pregnant women [5].
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aminophen for fever, headache or myalgia. Aspirin must be
avoided because of the risks of bleeding in those with throm-
bocytopenia [16] and increasing Reye's syndrome in children [4].
Non steroidal anti-inﬂammatory drugs are also not suggested
because of the increased risk of hemorrhagic syndrome [22].
Enough rehydration for ﬂuid loss should be applied. It is
necessary to diagnose neurological complications especially
GBS for early prescription of intravenous immunoglobulins [4].
Based on earlier studies, some of the drugs that target hep-
atitis C can have some special effects on ZIKV. Anti-malarial
hydroxychloroquine is an autophagy inhibitor and in vitro
testing has shown inhibition of dengue virus. Moreover, amo-
diaquine works via blockage of autophagy and inhibits Zika
virus pathogenicity. Immunotherapeutic strategies may propose
hope for reducing clinical complications from ZIKV including
GBS. Additionally, prophylactic and therapeutic use of cross-
reactive neutralizing monoclonal antibodies for ﬂavivirus in-
fections has been shown to be inﬂuential in animals [23].
9. Prevention
There is no vaccine available for ZIKV. At present, there are
approved vaccines for four ﬂavivirus diseases. Both inactivated
and live attenuated virus vaccines can be applied to ZIKV. Other
vaccine approaches include subunit, DNA and viral vector
vaccine platforms, all of which enclose or express ZIKV struc-
tural proteins [4,5,16].
Flaviviruses are inactivated by temperatures above 56 C for at
least 30min, UV light and gamma radiation. The viruses are known
to be vulnerable to disinfectants such as 1% sodium hypochlorite,
2% glutaraldehyde, 70% ethanol, 3%–6% hydrogen peroxide and
3%–8% formaldehyde. ZIKV is inactivated by potassium per-
manganate, and ether [14,19].
Inhabitants in or travelers to affected places should remain
inside with air conditioning, window and door screens if plau-
sible, wear long sleeves, use permethrin smeared clothes and
equipment and use insect repellents when outside. Insect re-
pellents encompassing N,N-diethyl-m-toluamide should be
attached for children older than two months, pregnant and
lactating women. For people coming back from affected areas to
non affected places, it is important to use insect repellents for at
least a further fourteen days [4]. Most importantly, World Health
Organization has recommended that pregnant women should get
safety measures to keep away from making contact with all
potential vectors until the epidemic is over [16,17,36,37].
Regarding blood transfusion, testing of blood donors is
suggested. When an outbreak happens, blood donation should be
temporary discontinued. In non-endemic places, using pre-
donation questionnaire is helpful to screen donors who
recently traveled to affected areas and delay of blood donation
from these donors until at least fourteen days after returning
from affected places should be done. It is substantial to test
donated organs of individuals who had history of travel to
affected regions for ZIKV. Returned men travelers should persist
to use condoms with pregnant sex partner all over the time of
pregnancy [4].
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